Global Influenza Vaccines Market Outlook 2018-2028 - Visiongain Report

LONDON, July 2, 2018 /PRNewswire/ --

Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain' s new study tells you and tells you NOW.

In this brand new 138-page report you find 63 in-depth tables, charts and graphs - all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Visiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
• Trivalent Influenza Vaccines (TIV)
• Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:
• Sanofi Pasteur
• GSK
• Seqirus
• AstraZeneca
• Protein Science Corporation.
• Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal Influenza vaccines in development
• Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:
• Fluzone / VaxiGrip
• Seqirus
• Fluarix / FluLaval
• FluMist / Fluenz
• FluBlok
• Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:
• United States
• Japan
• The EU 5 - Germany, France, United Kingdom, Italy and Spain.
• Brazil, Russia, India and China

Who should read this report?
• Anyone within the influenza vaccines value chain.
• Pharmaceutical companies
• Vaccine manufacturers
• Healthcare biotech companies
• Generics and biosimilar producers
• Drug delivery companies and other technology providers
• Contract/clinical research organisations (CROs)
• Pharma contract manufacturers,
• Pharma/healthcare wholesale and distribution companies
• Medical device companies
• Healthcare diagnostics companies
• R&D specialists
• Business development managers
• Marketing managers
• Technologists
• Suppliers
• Investors
• Banks
• Government agencies
• Contractors

Visiongain's study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed - get our report now.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/global-influenza-vaccines-market-outlook-2018-2028

Advisory Committee for Immunization Practices
Astellas Pharmaceuticals
AstraZeneca
Bharat Immunologicals and Biologicals Corporation Limited
Binnopharm
Bio Farma 
bioCSL
BioManguinhos/Oswaldo Cruz Foundation
BiondVax
BiondVax
Bionor
Biremx
Brazilian Ministry of Health
Butantan Institute
Cabtacuzino Institute
Center for Biologics Evaluation and Research
Centers for Disease Control and Prevention (CDC)
Centre for Disease Control and Prevention
Chemo-Sero-Therapeutic Research Institute
China National Biotech Group
China's National Regulatory Authority
Chinese Food and Drug Administration
ClearPath
CSL
CureVac
Daiichi Sankyo
Developing Countries Vaccine Manufacturers Network (DCVMN)
Dynavax
Flanders Institute
Food and Drug Administration (FDA)
FORT
Fresenius Pharmaceuticals
Gamma Vaccines
Gavi Alliance
Glaxo Smith Klein
GlaxoWellcome
Global Influenza Programme 
Governmental Pharmaceutical Organization (GPO)
Green Cross Corporation
Grippol
Health Service Bureau, Japan
Hualan Bio
Immune Targeting Systems
Indian Association of Paediatrics
International Vaccine Access Center (IVAC) 
Janssen Pharmaceuticals
Jenner Institute, University of oxford
Johnson & Johnson
Krka Pharmaceuticals
Medicago
Medicare
Medicines and Healthcare products Regulatory Agency (MHRA)
MedImmune
Merck
Mitsubishi Tanabe Pharma 
MSD Pharmaceuticals
National Health Service, UK
Netherlands Vaccine Institute
Novartis
Organisation for Economic Co-operation and Development
Panacea Biotech
Partnership for Influenza Vaccine Introduction
Petrovax
Pfizer
Protein Science Corporation
Razi Institute 
Sanofi Pasteur
Seqirus 
Serum Institute of India (SLL)
Servizio Sanitario Nationale
Shionogi Pharmaceuticals
Sinopharm
Sistema Unico de Saude
SmithKline Beecham
Takeda Pharmaceuticals
Terumo Pharmaceuticals
The Ministry of Health, Labour and Welfare, Japan
The Scripps Research Institute
Torlak Institut
Ultriks
US Department of Health and Human Services
Vacsera
VaxInnate
VaxInnate Corporation 
WHO Strategic Advisory Group of Experts
World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com